log in search issues home
about us
subscriptions
from the editor
sample issue
customer service
CME
special offers

Purchase this Article

In Brief

The US Food and Drug Administration approved an extended-release injectable suspension preparation of olanzapine (Zyprexa Relprevv) on December 11, 2009, for the treatment of schizophrenia in adults. It is a long-acting atypical antipsychotic for deep intramuscular gluteal injection. We reviewed this…

 


To view the rest of this article, please:

 
For current
BTP subscribers
Purchase access
to all articles
Purchase this article
for $3 (USD)

 
PO Box 42650, Tucson, AZ 85733-2650 • Phone 1-800-700-9589(US) or 1-520-572-2039 (Outside US) • Fax 1-520-825-3793 • Email information@btpnews.com
Contents of entire Website and Biological Therapies in Psychiatry Newsletter are ©2010 Gelenberg Consulting & Publishing All rights are reserved. Any unauthorized reproduction constitutes a violation of federal law.

Disclaimer: This publication provides general coverage of its subject area. It is sold with the understanding that the authors and publisher are not engaged in rendering medical or other professional advice or services. If medical or other expert advice is required, a competent professional should be consulted. The authors and publisher shall not be responsible for any damages resulting from any error, inaccuracy, or omission contained in this publication.